FDA Brief

Warning letters Drugs

FDA warning letter to

ibeautistore.com

High riskIssued Apr 24Posted May 5Center for Drug Evaluation and Research (CDER)

ibeautistore.com sold Umary hyaluronic acid capsules as a supplement, but FDA found hidden diclofenac, dexamethasone, and omeprazole.

What happened

FDA reviewed https://ibeautistore.com/ in March 2026 and obtained a sample of “New Hyaluronic Acid 850 mg Sealed 30 Caps,” labeled “Umary,” through the website. Laboratory analysis found the undeclared active drug ingredients diclofenac, dexamethasone, and omeprazole. No inspection dates were given.

What FDA found

  1. The product is an unapproved new drug—a drug sold without FDA approval—because no approved application is in effect for it.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. The product is misbranded because its labeling does not declare that it contains diclofenac, dexamethasone, and omeprazole.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  3. Because it contains diclofenac and dexamethasone, which were approved as drugs before being marketed as dietary supplements, the product is excluded from the definition of a dietary supplement.

    section 201(ff)(3)(B)(i), 21 U.S.C. 321(ff)(3)(B)(i)
  4. Website claims that the product hydrates skin and joints and addresses aging and wrinkles show it is intended for use as a drug.

    section 201(g)(1), 21 U.S.C. 321(g)(1)
  5. The product is a new drug that is not generally recognized as safe and effective for its labeled uses.

    section 201(p), 21 U.S.C. 321(p)
  6. Introducing or delivering the unapproved and misbranded drug into interstate commerce is prohibited.

    sections 301(a), 301(d), and 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d), and 355(a)

What FDA wants

FDA asks the company to notify it in writing within fifteen working days of the steps taken to correct the violations and prevent recurrence, with related documentation. If corrective action cannot be completed in that time, the company must state the reason and the time within which it will complete the correction.

Who should pay attention

  • online sellers of supplements and hyaluronic acid products
  • consumers who bought or may buy Umary products
  • platforms and brands hosting third-party product listings

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk